Product Development and Technology - The DeepView System has received UKCA marking for burn indications, with initial sales anticipated to begin in the UK in 2026[18]. - The DeepView System's validation study enrolled 164 patients, showing superiority in sensitivity and meeting non-inferiority in specificity compared to clinician assessments[28]. - The DeepView System can provide a "Day One" assessment of a wound's healing potential, significantly reducing the current decision time from 21 days to 1 day[40]. - The DeepView SnapShot M, a portable diagnostic tool, has received over $7.2 million in funding for development, primarily for military and emergency care settings[31]. - The 3D wound measurement technology aims to enhance the accuracy of total body surface area affected by burns, improving treatment decisions[33]. - The DeepView System's imaging technology processes images in approximately 20 to 25 seconds, extracting millions of pixels of data for AI model optimization[39]. - The DeepView System is the only AI-enabled wound imaging technology that correlates raw physiological data to predictive wound healing outcomes[51]. - The DeepView System requires a De Novo classification due to its novel approach to wound healing prediction, which is not substantially equivalent to any existing device on the market[116]. Funding and Financials - The company has secured approximately $282.5 million in funding from U.S. government contracts since 2013, with $272.9 million from BARDA, and a new contract executed on September 27, 2023, providing up to $150 million[24]. - The company executed a new contract with BARDA on September 27, 2023, providing up to $150.0 million in funding, including an initial award of approximately $54.9 million for the clinical validation and FDA clearance of the DeepView System[72]. - The BARDA contract is the largest single source of revenue for the company, with a prior contract option valued at approximately $21.9 million replaced by the new contract[77]. - The company incurred a net loss of $7.5 million for the year ended December 31, 2025, compared to a net loss of $15.1 million for the year ended December 31, 2024, with an accumulated deficit of approximately $55.8 million as of December 31, 2025[71]. - The company expects its cash and cash equivalents, along with remaining funding from BARDA and other agreements, to be sufficient to meet capital requirements for at least the next 12 months[84]. - The company completed an equity financing and entered into a long-term debt financing agreement with Avenue Capital Group, with an initial draw-down of $8.5 million and a second tranche contingent upon FDA clearance and a $7.0 million equity raise[83]. Market Strategy and Commercialization - The company plans to target approximately 140 burn centers, 700 trauma centers, and 5,400 federal and community hospitals in the U.S. for the DeepView System's deployment[25]. - The company plans to expand its sales and marketing teams to support commercialization efforts in the U.S. and abroad[53]. - The total addressable market includes over 57,000 clinical care sites in the U.S. and over 20,000 in the UK and EU, with potential expansion into the Middle East[43]. - The company aims to establish strong relationships with leading U.S. hospitals to promote the DeepView System, leveraging partnerships to increase awareness and adoption[149]. - The commercial success of the DeepView System will depend on market acceptance by clinicians, with risks of slow market development adversely affecting business results[147]. - Third-party payor coverage and reimbursement are critical for the commercial success of the DeepView System; inadequate coverage could negatively impact sales and financial prospects[156]. Regulatory and Compliance Challenges - The regulatory review process for the DeepView technology is expensive and uncertain, with no guarantee of obtaining necessary approvals or market authorization[90]. - The company must receive 510(k) clearance, PMA approval, or De Novo classification to market new medical devices in the U.S., with potential delays and high costs associated with the PMA route[93]. - Compliance with EU Medical Devices Regulation is required to affix the CE mark, which is essential for selling devices in the EU[94]. - The company relies on third parties for clinical trials, and any failure in their performance could hinder obtaining necessary regulatory approvals[99]. - The FDA and other regulatory bodies can delay or deny market authorization for various reasons, affecting the ability to generate revenue from the DeepView System[98]. - The company may face enforcement actions if marketing claims exceed the scope of permitted indications, leading to potential fines or product sales cessation[114]. Intellectual Property and Competitive Landscape - The company has 13 issued and allowed U.S. patents and 21 international patents, with additional applications pending[62]. - The company must obtain and maintain adequate intellectual property protection to prevent competitors from commercializing similar products, which is critical for its market position[206]. - The proprietary AI algorithm used in the SnapShot MSI system is not patent protected, posing a risk to the competitive advantage of the DeepView System[212]. - The company acknowledges the uncertainty surrounding the enforceability and validity of its patents, which may be challenged in courts or patent offices[213]. - The company faces potential challenges from third parties that may seek to market similar products, necessitating the defense of its patents[215]. Operational and Management Considerations - The company employs 65 full-time employees and plans to hire more in 2026 to support operations, sales, and marketing[66]. - The company anticipates significant growth in operations, particularly in manufacturing and sales, which may strain management and operational resources[179]. - The company is dependent on senior management and key personnel, and their loss could adversely affect business operations[180]. - The company plans to expand its workforce, including in Europe, to support its growth strategy, which may lead to significant costs and operational challenges[182]. - The company lacks experience in marketing and selling the DeepView System, which may hinder its ability to establish a direct sales force and achieve revenue growth[152]. Risks and Uncertainties - The company may need additional funding to finance operations and product development, with no assurance that it can raise capital on favorable terms[85]. - The company faces intense competition from established manufacturers with greater resources, which may limit market penetration and pricing power[160]. - The company faces risks associated with international expansion, including regulatory, operational, and financial challenges, which could adversely affect business operations[204]. - The company relies on third-party manufacturers, exposing it to risks related to product quality and compliance with regulatory standards[128]. - The company may incur significant costs from cyber-attacks, including liability for stolen assets and damage to network infrastructure, which could harm its financial condition[191].
ROSECLIFF ACQU(RCLF) - 2025 Q4 - Annual Report